TY - JOUR
T1 - Immune Reconstitution After Allogeneic Haematopoietic Cell Transplantation
T2 - From Observational Studies to Targeted Interventions
AU - Yanir, Asaf
AU - Schulz, Ansgar
AU - Lawitschka, Anita
AU - Nierkens, Stefan
AU - Eyrich, Matthias
N1 - Copyright © 2022 Yanir, Schulz, Lawitschka, Nierkens and Eyrich.
PY - 2021
Y1 - 2021
N2 - Immune reconstitution (IR) after allogeneic haematopoietic cell transplantation (HCT) represents a central determinant of the clinical post-transplant course, since the majority of transplant-related outcome parameters such as graft-vs.-host disease (GvHD), infectious complications, and relapse are related to the velocity, quantity and quality of immune cell recovery. Younger age at transplant has been identified as the most important positive prognostic factor for favourable IR post-transplant and, indeed, accelerated immune cell recovery in children is most likely the pivotal contributing factor to lower incidences of GvHD and infectious complications in paediatric allogeneic HCT. Although our knowledge about the mechanisms of IR has significantly increased over the recent years, strategies to influence IR are just evolving. In this review, we will discuss different patterns of IR during various time points post-transplant and their impact on outcome. Besides IR patterns and cellular phenotypes, recovery of antigen-specific immune cells, for example virus-specific T cells, has recently gained increasing interest, as certain threshold levels of antigen-specific T cells seem to confer protection against severe viral disease courses. In contrast, the association between IR and a possible graft-vs. leukaemia effect is less well-understood. Finally, we will present current concepts of how to improve IR and how this could change transplant procedures in the near future.
AB - Immune reconstitution (IR) after allogeneic haematopoietic cell transplantation (HCT) represents a central determinant of the clinical post-transplant course, since the majority of transplant-related outcome parameters such as graft-vs.-host disease (GvHD), infectious complications, and relapse are related to the velocity, quantity and quality of immune cell recovery. Younger age at transplant has been identified as the most important positive prognostic factor for favourable IR post-transplant and, indeed, accelerated immune cell recovery in children is most likely the pivotal contributing factor to lower incidences of GvHD and infectious complications in paediatric allogeneic HCT. Although our knowledge about the mechanisms of IR has significantly increased over the recent years, strategies to influence IR are just evolving. In this review, we will discuss different patterns of IR during various time points post-transplant and their impact on outcome. Besides IR patterns and cellular phenotypes, recovery of antigen-specific immune cells, for example virus-specific T cells, has recently gained increasing interest, as certain threshold levels of antigen-specific T cells seem to confer protection against severe viral disease courses. In contrast, the association between IR and a possible graft-vs. leukaemia effect is less well-understood. Finally, we will present current concepts of how to improve IR and how this could change transplant procedures in the near future.
KW - graft-vs.-host disease
KW - graft-vs.-leukaemia effect
KW - immune reconstitution
KW - infectious complications
KW - peripheral expansion
KW - T-cell receptor repertoire diversity
KW - thymic function
KW - T-cell receptor repertoire diversity
KW - graft-vs.-host disease
KW - graft-vs.-leukaemia effect
KW - immune reconstitution
KW - infectious complications
KW - peripheral expansion
KW - thymic function
UR - http://www.scopus.com/inward/record.url?scp=85123407267&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/59d16c88-99a1-3e31-bf39-2b16fd4d369d/
U2 - 10.3389/fped.2021.786017
DO - 10.3389/fped.2021.786017
M3 - Article
C2 - 35087775
AN - SCOPUS:85123407267
SN - 2296-2360
VL - 9
SP - 786017
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
M1 - 786017
ER -